STOCK TITAN

Health Catalyst (HCAT) SEC Filings, May-Jun 2026

HCAT NASDAQ

Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.

The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.

Rhea-AI Summary

Larson-Green Julie reported acquisition or exercise transactions in this Form 4 filing.

Health Catalyst, Inc. director Julie Larson-Green received an equity grant of 12,710 shares of common stock in the form of restricted stock units. The award was granted under the company’s 2019 Stock Option and Incentive Plan at no cash cost and vested in full on June 1, 2026. Following this compensation grant, she directly holds 94,644 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.86%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. is asking stockholders to act on four main items at its 2026 virtual annual meeting on July 16, 2026. Investors will vote to elect two Class I directors, Justin Spencer and Mathew Arens, to terms ending at the 2029 annual meeting, and to ratify Ernst & Young LLP as independent auditor for the year ending December 31, 2026.

Stockholders will also cast an advisory, non-binding “say‑on‑pay” vote on 2025 compensation for named executive officers. A key governance proposal would restate the certificate of incorporation to phase out the classified board so that, beginning with the 2029 annual meeting, all directors are elected annually. The record date is May 22, 2026, when 73,894,020 common shares were outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.86%
Tags
proxy
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) affiliate Benjamin Albert submitted a Form 144 notice proposing the sale of 336 shares of Common Stock (restricted) with a trade date of 06/01/2026. The filing lists prior restricted stock dispositions by the same holder during the past three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
other
Rhea-AI Summary

Health Catalyst, Inc. reports a proposed sale of 18,804 shares of Common Stock under Form 144. The filing lists these as restricted stock associated with compensation, with the proposed sale date of 06/01/2026.

The excerpt also shows 26,970 shares sold in the prior three months and indicates 73,894,020 shares outstanding as of 06/01/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
other
-
Rhea-AI Summary

Health Catalyst, Inc. proposed the sale of 8,519 shares of Restricted Stock on 06/01/2026 under a Form 144 notice. The filing shows these shares are linked to compensation. The filing also reports 13,836 shares sold on 03/02/2026 by Linda Llewelyn, with proceeds noted as $22,966.38.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
other
-
Rhea-AI Summary

Health Catalyst, Inc. filed a Rule 144 notice to sell 13,779 shares of restricted common stock on 06/01/2026 described as compensation-related restricted stock. The filing lists an earlier restricted stock sale by Benjamin Landry on 03/02/2026 involving 20,838 shares and a figure 34,589 shown in the excerpt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
other
Rhea-AI Summary

Health Catalyst, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on July 16, 2026. Stockholders of record as of May 22, 2026 may vote on electing two Class I directors, ratifying Ernst & Young LLP as auditor, an advisory ``say-on-pay'' for 2025 executive compensation, and a charter restatement to phase out the classified board (annual elections beginning 2029), each with the voting thresholds described in the Proxy Statement.

The board recommends votes FOR all proposals. Proxy delivery will be electronic via the Notice of Internet Availability and the Company will file voting results on Form 8-K after the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
proxy
-
Rhea-AI Summary

Health Catalyst, Inc. amendment reports beneficial ownership stakes held by related reporting persons as of 03/31/2026. The filing shows Stoney Lonesome HF LP holds 6,079,539 shares (approximately 8.3%) and Drake Helix Holdings, LLC holds 227,706 shares (approximately 0.3%).

The filing states a total share count of 73,586,183 shares outstanding as of 03/05/2026 (source: issuer's Form 10-K). Related entities Coghill Capital Management, LLC and CDC Financial, Inc. are disclosed as holding or deemed to hold the combined positions, and Clint D. Coghill is identified as owning 1,100 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
ownership
-
Rhea-AI Summary

Health Catalyst, Inc. reported weaker first-quarter 2026 results, highlighted by a large non-cash goodwill impairment. Total revenue was $70.8 million, down from $79.4 million a year earlier, with technology revenue at $49.5 million and professional services at $21.3 million.

Operating expenses rose sharply due to a $95.5 million goodwill impairment in the technology reporting unit, driving loss from operations to $106.5 million versus $20.2 million last year. Net loss widened to $111.0 million or $1.53 per share, compared with a $23.7 million loss or $0.35 per share.

Despite the loss, net cash provided by operating activities improved to $18.5 million from $0.3 million, and cash and cash equivalents rose to $59.9 million with short-term investments of $49.0 million. The company carried a variable-rate term loan with $160.4 million principal outstanding and total stockholders’ equity of $138.1 million as of March 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
quarterly report
Rhea-AI Summary

Health Catalyst, Inc. reported first quarter 2026 results showing lower revenue but stronger non-GAAP profitability alongside a major accounting charge. Total revenue was $70.8 million, down 11% from $79.4 million a year earlier, with gross margin improving to 39% from 36%.

The company recorded a sizeable $95.5 million goodwill impairment in its Technology reporting unit, driving a GAAP net loss of $111.0 million, or $1.53 per share, compared with a $23.7 million loss in 2025. Excluding non-cash and non-recurring items, Adjusted EBITDA rose 46% to $9.1 million and adjusted net income was $1.2 million, or $0.02 per diluted share.

Management issued guidance for 2026, expecting full-year revenue of $260–$265 million and Adjusted EBITDA of $30–$33 million, and highlighted a strategic reset of its operating model and ongoing migration from DOS to Ignite, which may cause some client churn and down-sell.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
current report

FAQ

How many Health Catalyst (HCAT) SEC filings are available on StockTitan?

StockTitan tracks 127 SEC filings for Health Catalyst (HCAT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Health Catalyst (HCAT)?

The most recent SEC filing for Health Catalyst (HCAT) was filed on November 13, 2026.